• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[前列腺癌的雄激素剥夺治疗。适应症及全身影响]

[Androgen deprivation therapy in prostate cancer. Indication and systemic consequences].

作者信息

Rohayem J, Kliesch S

机构信息

Centrum für Reproduktionsmedizin und Andrologie, WHO Kooperationszentrum, EAA Ausbildungszentrum, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1, Gebäude D11, 48149, Münster, Deutschland.

出版信息

Urologe A. 2012 Apr;51(4):557-64; quiz 565-6. doi: 10.1007/s00120-012-2808-7.

DOI:10.1007/s00120-012-2808-7
PMID:22476802
Abstract

Androgen deprivation therapy (ADT) is effective in prolonging the progression free survival of patients with symptomatic/metastatic prostate cancer (PC). The reduction of clinical symptoms of tumour disease and the reduction of tumour growth and metastatic dissemination is accompanied by systemic consequences of testosterone deficiency. These are hot flushes, fatigue due to reduction of muscular strength and muscle mass as well as anaemia. Moreover, patients develop cognitive impairment und depressive mood. Weight gain with insulin resistance, disturbances of lipid metabolism and gynecomastia are other effects of androgen deficiency. A decrease in bone mineral density may lead to an increased susceptibility to bone fractures. There are several options to reduce these side effects of ADT, e.g. physical activity, dietary supplementation, tailored pharmacological therapy and psychotherapy. The knowledge of these adjuvant treatment options, despite their palliative character, is relevant to optimize the quality of life of these patients.

摘要

雄激素剥夺疗法(ADT)可有效延长有症状/转移性前列腺癌(PC)患者的无进展生存期。肿瘤疾病临床症状的减轻以及肿瘤生长和转移扩散的减少伴随着睾酮缺乏的全身性后果。这些后果包括潮热、因肌肉力量和肌肉量减少导致的疲劳以及贫血。此外,患者会出现认知障碍和抑郁情绪。体重增加伴胰岛素抵抗、脂质代谢紊乱和男性乳房发育是雄激素缺乏的其他影响。骨矿物质密度降低可能导致骨折易感性增加。有多种方法可减少ADT的这些副作用,例如体育活动、膳食补充、针对性的药物治疗和心理治疗。尽管这些辅助治疗方法具有姑息性质,但了解它们对于优化这些患者的生活质量至关重要。

相似文献

1
[Androgen deprivation therapy in prostate cancer. Indication and systemic consequences].[前列腺癌的雄激素剥夺治疗。适应症及全身影响]
Urologe A. 2012 Apr;51(4):557-64; quiz 565-6. doi: 10.1007/s00120-012-2808-7.
2
Androgen deprivation therapy: evidence-based management of side effects.雄激素剥夺疗法:副作用的循证管理。
BJU Int. 2013 Apr;111(4):543-8. doi: 10.1111/j.1464-410X.2012.11774.x. Epub 2013 Jan 25.
3
Neuropsychiatric Impact of Androgen Deprivation Therapy in Patients with Prostate Cancer: Current Evidence and Recommendations for the Clinician.雄激素剥夺疗法对前列腺癌患者的神经精神影响:当前证据和临床建议。
Eur Urol Focus. 2020 Nov 15;6(6):1170-1179. doi: 10.1016/j.euf.2020.05.014. Epub 2020 Jul 18.
4
Complications of androgen deprivation therapy in prostate cancer.前列腺癌雄激素剥夺治疗的并发症
Curr Opin Urol. 2009 May;19(3):322-6. doi: 10.1097/MOU.0b013e32832a082c.
5
Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?雄激素剥夺疗法在前列腺癌男性患者中的应用:如何监测和治疗其副作用?
Clin Endocrinol (Oxf). 2011 Mar;74(3):289-93. doi: 10.1111/j.1365-2265.2010.03939.x.
6
Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.接受雄激素剥夺治疗的非转移性前列腺癌患者的骨骼和代谢健康。
Med J Aust. 2011 Mar 21;194(6):301-6. doi: 10.5694/j.1326-5377.2011.tb02979.x.
7
Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management.雄激素剥夺疗法治疗前列腺癌:预期的副作用及其处理。
Curr Opin Support Palliat Care. 2010 Sep;4(3):147-52. doi: 10.1097/SPC.0b013e32833bd913.
8
Nutrition care guidelines for men with prostate cancer undergoing androgen deprivation therapy: do we have enough evidence?雄激素剥夺治疗的前列腺癌男性的营养护理指南:我们有足够的证据吗?
Prostate Cancer Prostatic Dis. 2019 May;22(2):221-234. doi: 10.1038/s41391-018-0099-9. Epub 2018 Oct 2.
9
Long-term effects of androgen deprivation therapy in prostate cancer patients.雄激素剥夺疗法对前列腺癌患者的长期影响。
Clin Endocrinol (Oxf). 2002 Jun;56(6):779-86. doi: 10.1046/j.1365-2265.2002.01551.x.
10
Side effects of androgen deprivation therapy: monitoring and minimizing toxicity.雄激素剥夺治疗的副作用:监测与毒性最小化
Urology. 2003 Feb;61(2 Suppl 1):32-8. doi: 10.1016/s0090-4295(02)02397-x.

引用本文的文献

1
[Antihormonal therapy in prostate cancer : Side effects].[前列腺癌的抗激素治疗:副作用]
Urologe A. 2017 Apr;56(4):465-471. doi: 10.1007/s00120-017-0340-5.

本文引用的文献

1
Methylphenidate: established and expanding roles in symptom management.哌甲酯:在症状管理中既有的和不断扩展的作用。
Am J Hosp Palliat Care. 2012 Sep;29(6):483-90. doi: 10.1177/1049909111427029. Epub 2011 Dec 4.
2
Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis.雄激素剥夺疗法治疗前列腺癌患者的双膦酸盐治疗:系统评价和荟萃分析。
Prostate Cancer Prostatic Dis. 2012 Mar;15(1):36-44. doi: 10.1038/pcan.2011.4. Epub 2011 Sep 6.
3
Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial.
915例转移性前列腺癌患者接受胃肠外雌激素治疗或联合雄激素剥夺治疗期间,预处理心血管疾病作为危险因素的意义:一项随机试验中心血管事件的评估
Scand J Urol Nephrol. 2011 Nov;45(5):346-53. doi: 10.3109/00365599.2011.585820. Epub 2011 May 31.
4
Abiraterone and increased survival in metastatic prostate cancer.阿比特龙与转移性前列腺癌患者的生存获益
N Engl J Med. 2011 May 26;364(21):1995-2005. doi: 10.1056/NEJMoa1014618.
5
Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer.连续与间歇性雄激素剥夺疗法治疗转移性前列腺癌。
Urol Oncol. 2013 Jul;31(5):549-56. doi: 10.1016/j.urolonc.2011.03.008. Epub 2011 May 10.
6
Fracture risk in men with prostate cancer: a population-based study.前列腺癌男性的骨折风险:一项基于人群的研究。
J Bone Miner Res. 2011 Aug;26(8):1808-15. doi: 10.1002/jbmr.405.
7
Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.卡巴他赛:转移性去势抵抗性前列腺癌的新型二线治疗药物。
Drug Des Devel Ther. 2011 Mar 10;5:117-24. doi: 10.2147/DDDT.S13029.
8
Evidence-based cognitive rehabilitation: updated review of the literature from 2003 through 2008.循证认知康复:2003 年至 2008 年文献的最新回顾。
Arch Phys Med Rehabil. 2011 Apr;92(4):519-30. doi: 10.1016/j.apmr.2010.11.015.
9
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.EAU 前列腺癌指南。第二部分:晚期、复发性和去势抵抗性前列腺癌的治疗。
Eur Urol. 2011 Apr;59(4):572-83. doi: 10.1016/j.eururo.2011.01.025. Epub 2011 Jan 25.
10
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.前列腺癌中的雄激素剥夺疗法与心血管风险:美国心脏协会、美国癌症协会和美国泌尿外科学会的科学咨询意见:得到美国放射肿瘤学会认可
Circulation. 2010 Feb 16;121(6):833-40. doi: 10.1161/CIRCULATIONAHA.109.192695. Epub 2010 Feb 1.